Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting Caspase-3 as Dual Therapeutic Benefits by RNAi Facilitating Brain-Targeted Nanoparticles in a Rat Model of Parkinson’s Disease

13 May 2013

Abstract excerpt

The activation of caspase-3 is an important hallmark in Parkinson's disease. It could induce neuron death by apoptosis and microglia activation by inflammation. As a result, inhibition the activation of caspase-3 would exert synergistic dual effect in brain in order to prevent the progress of Parkinson's disease. Silencing caspase-3 genes by RNA interference could inhibit the activation of caspase-3. We developed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer's disease research and treatments
Share to Neuroscience and Neuropharmacology Research
Share to RNA Interference and Gene Delivery

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23675438
DOI: 10.1371/journal.pone.0062905

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting Caspase-3 as Dual Therapeutic Benefits by RNAi Facilitating Brain-Targeted Nanoparticles in a Rat Model of Parkinson’s DiseasePMID 23675438Read ↗

Therapeutic effects of engineered exosome-based miR-25 and miR-181a treatment in spinocerebellar ataxia type 3 mice by silencing ATXN3Semantic proximity Read ↗

Intravenous administration of brain-targeted stable nucleic acid lipid particles alleviates Machado-Joseph disease neurological phenotype.Semantic proximity Read ↗

In vivo self-assembled siRNAs within small extracellular vesicles attenuate LRRK2-induced neurodegeneration in Parkinson's disease modelsSemantic proximity Read ↗

Viral vectors in neurodegenerative diseases: immune responses and therapeutic applicationsSemantic proximity Read ↗

Dendrimer for targeted drug delivery and Vaccine and Immunostimulatory: applications and methodsSemantic proximity Read ↗

Targeted exosome coating gene-chem nanocomplex as “nanoscavenger” for clearing α-synuclein and immune activation of Parkinson’s diseaseSemantic proximity Read ↗

Targeted delivery of BACE1 siRNA for synergistic treatment of Alzheimer's diseaseSemantic proximity Read ↗

Asn194Lys mutation in RVG29 peptide increases GFP transgene delivery by endocytosis to neuroblastoma and astrocyte cells.Semantic proximity Read ↗

Novel gene delivery systems for brain targetingSemantic proximity Read ↗

Attenuation of Vesicular Stomatitis Virus Encephalitis through MicroRNA TargetingSemantic proximity Read ↗

Messenger RNA-based therapeutics for brain diseases: An animal study for augmenting clearance of beta-amyloid by intracerebral administration of neprilysin mRNA loaded in polyplex nanomicellesSemantic proximity Read ↗

Genetic silencing of striatal CaV1.3 prevents and ameliorates levodopa dyskinesiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.